Neutralizing Antibodies Making Their Mark in Next Wave of Biologics
In the last couple of years, there has been heightened interest in the development of Monoclonal antibodies (mAbs) as therapeutics as they have shown great promise in the treatment of serious or untreatable conditions such as cancer. This is partly due to their highly specific targeting of antigens as well as their high efficacy and fewer side effects. Vaccines and effective antibody therapeutics will play an integral role in keeping the ongoing COVID-19 pandemic and emerging variants under control.
Neutralizing Antibodies are an example of molecules that will play a critical role in vaccine and therapeutics development as they can bind to a virus in a manner that blocks infection. Neutralizing Antibodies can be isolated from plasma of convalescent patients and have become a major focus for researchers around the globe in the race to a better understanding of the mechanisms of action (MOA) against the receptor-binding domains (RBD) of the SARS-CoV-2 Spike protein.